Patent Claims

1. Stable formulation of a solution consisting of xylometazoline hydrochloride and oxymetazoline hydrochloride as active substance, a solvent which is pharmacologically acceptable for nasal administration, an adjuvant selected from among sorbitol and/or glycerol and an inorganic pH buffer.

2. Formulation according to claim 1, characterised in that the active substance is present in a concentration of between 0.01 and 1.0% by weight, preferably between 0.01 and 0.5% by weight and most preferably between 0.05 and 0.1% by weight.

3. Formulation according to one of claims 1 and 2, characterised in that the solvent is water.

4. Formulation according to one of claims 1 and 2, characterised in that the solvent is a mixture of ethanol and water.

5. Formulation according to one of claims 1 to 4, characterised in that the proportion of adjuvant in the solution is 1 to 10% by weight, preferably 2 to 6% by weight.

6. Formulation according to claim 5, characterised in that the adjuvant is 3.5 to 4.5% by weight, preferably 4.0% by weight, of sorbitol.

7. Formulation according to claim 6, characterised in that the adjuvant is 2.0 to 2.8% by weight, preferably 2.4% by weight, of glycerol.

8. Formulation according to one of claims 1 to 7, characterised in that the solution contains a sodium and/or potassium phosphate buffer or a sodium and/or potassium borate buffer.

9. Formulation according to one of claims 1 to 8, characterised in that the solution contains a monosodium dihydrogen-disodium monohydrogen phosphate buffer and/or monopotassium dihydrogen-dipotassium monohydrogen phosphate buffer.

10. Formulation according to one of claims 1 to 9, characterised in that the solution is adjusted to a pH of 5.0 to 6.8, preferably 5.5 to 6.8, most preferably 5.8 to 6.0.

11. Formulation according to one of claims 1 to 10, characterised in that the formulation contains an oligodynamically active substance.

12. Formulation according to claim 11, characterised in that the oligodynamic substance is silver or silver ions.

13. Formulation according to one of claims 1 to 12, characterised in that the formulation contains only xylometazoline hydrochloride as active substance.

14. Formulation according to one of claims 1 to 12, characterised in that the formulation contains only oxymetazoline hydrochloride as active substance.

15. Use of a formulation according to claims 1 to 14 together with an inhaler having silver-containing elements in the region between the active substance reservoir and the sprayhead.

16. Use of the formulation according to one of claims 1 to 13 as a rhinological agent.